Business, energy, technology, markets and global industry news from Business News Today

Foundayo

PharmaDeviceNews Foundayo
Pharma & Biotech

Evidation GLP-1 study reveals major growth runway but exposes widening access gaps

Discover how Evidation’s 165,000-person study reveals GLP-1 growth potential, access gaps and persistence risks shaping obesity care. Read more.

Read More
Representative image: Eli Lilly’s expanding diabetes and obesity drug pipeline, including Foundayo, Mounjaro and retatrutide, highlights the growing race to reshape cardiometabolic care through oral GLP-1 therapies, injectable incretin drugs and next-generation clinical trial advances.
Pharma & Biotech

Can Eli Lilly’s Foundayo and retatrutide deepen its grip on the diabetes and obesity market?

Find out how Eli Lilly’s Foundayo and retatrutide data could reshape diabetes, obesity and cardiometabolic care.

Read More
Representative image of a modern U.S. pharmaceutical manufacturing campus, highlighting how Eli Lilly’s $4.5 billion Indiana expansion could strengthen domestic drug production capacity for obesity, diabetes and advanced genetic medicines.
Pharma & Biotech

Could Eli Lilly’s $4.5bn Indiana investment widen its lead in obesity and advanced therapies?

Obesity drug demand is outrunning pharma capacity. Eli Lilly’s Indiana bet shows manufacturing is now a strategic moat.

Read More
Representative image: Novo Nordisk’s Wegovy pill launch in the U.S. obesity drug market is illustrated through unbranded tablets, prescription growth data and healthcare market signals, reflecting rising demand for oral GLP-1 weight-loss treatments.
Pharma & Biotech

Can Novo Nordisk’s Wegovy pill reshape the obesity market before Eli Lilly catches up?

Novo Nordisk has the first-mover pill. Eli Lilly has the growth aura. Oral obesity drugs are turning access into the next GLP-1 battleground.

Read More
Representative image of an oral obesity treatment concept illustrating how Eli Lilly and Company’s Foundayo approval could widen access to GLP-1 weight loss therapy and reshape the next phase of the obesity drug market.
Pharma & Biotech

Eli Lilly and Company’s Foundayo approval could widen the obesity market faster than rivals expected

Eli Lilly and Company’s Foundayo approval could reshape obesity treatment. Read what the oral GLP-1 launch changes for clinicians, payers, and rivals.

Read More